- Home
- VCNX vs APTO Comparison
VCNX vs APTO Comparison
Compare VCNX & APTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCNX
- APTO
- Stock Information
- Founded
- VCNX 2001
- APTO 1986
- Country
- VCNX United States
- APTO Canada
- Employees
- VCNX N/A
- APTO N/A
- Industry
- VCNX Biotechnology: Pharmaceutical Preparations
- APTO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VCNX Health Care
- APTO Health Care
- Exchange
- VCNX Nasdaq
- APTO Nasdaq
- Market Cap
- VCNX 10.5M
- APTO 11.5M
- IPO Year
- VCNX N/A
- APTO N/A
- Fundamental
- Price
- VCNX $1.41
- APTO $0.18
- Analyst Decision
- VCNX
- APTO Strong Buy
- Analyst Count
- VCNX 0
- APTO 3
- Target Price
- VCNX N/A
- APTO $4.33
- AVG Volume (30 Days)
- VCNX 96.1K
- APTO 1.4M
- Earning Date
- VCNX 11-14-2024
- APTO 11-08-2024
- Dividend Yield
- VCNX N/A
- APTO N/A
- EPS Growth
- VCNX N/A
- APTO N/A
- EPS
- VCNX N/A
- APTO N/A
- Revenue
- VCNX $388,000.00
- APTO N/A
- Revenue This Year
- VCNX N/A
- APTO N/A
- Revenue Next Year
- VCNX N/A
- APTO N/A
- P/E Ratio
- VCNX N/A
- APTO N/A
- Revenue Growth
- VCNX N/A
- APTO N/A
- 52 Week Low
- VCNX $1.25
- APTO $0.13
- 52 Week High
- VCNX $13.02
- APTO $2.68
- Technical
- Relative Strength Index (RSI)
- VCNX 27.23
- APTO 29.73
- Support Level
- VCNX $3.34
- APTO $0.18
- Resistance Level
- VCNX $4.35
- APTO $0.22
- Average True Range (ATR)
- VCNX 0.45
- APTO 0.01
- MACD
- VCNX -0.19
- APTO 0.01
- Stochastic Oscillator
- VCNX 0.00
- APTO 22.50
About VCNX Vaccinex Inc.
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.
About APTO Aptose Biosciences Inc.
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.